Aptevo Therapeutics Inc. (NASDAQ:APVO – Get Free Report) dropped 7.1% on Tuesday . The stock traded as low as $4.38 and last traded at $4.42. 26,537 shares were traded during trading, a decline of 73% from the average daily volume of 96,504 shares. The stock had previously closed at $4.76.
Wall Street Analyst Weigh In
Several equities research analysts have recently issued reports on APVO shares. Wall Street Zen raised Aptevo Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, March 29th. Weiss Ratings downgraded Aptevo Therapeutics from a “sell (e+)” rating to a “sell (e)” rating in a research report on Wednesday, July 1st. One investment analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Aptevo Therapeutics has a consensus rating of “Hold”.
View Our Latest Stock Report on APVO
Aptevo Therapeutics Stock Performance
Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) last announced its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported ($6.41) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($6.41). Analysts anticipate that Aptevo Therapeutics Inc. will post -23.35 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Aptevo Therapeutics
A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Virtu Financial LLC acquired a new stake in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO – Free Report) in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 38,282 shares of the biotechnology company’s stock, valued at approximately $56,000. Virtu Financial LLC owned 1.16% of Aptevo Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 8.06% of the company’s stock.
Aptevo Therapeutics Company Profile
Aptevo Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, focused on the discovery and development of novel immunotherapies for oncology and autoimmune diseases. Founded in 2012 as a spin-off from Emergent BioSolutions, the company builds on expertise in protein engineering and translational research to create targeted biologics that engage the body’s immune system.
The company’s core technologies include the ADAPTIR platform, which enables the design of bispecific and multispecific protein scaffolds with customizable binding domains, and the KNOCKOUT platform, which incorporates non-natural amino acids to enhance therapeutic properties such as stability and half-life.
Featured Stories
- Five stocks we like better than Aptevo Therapeutics
- Confidence Is Back, But Earnings Show the Consumer Is Being Picky
- AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off
- 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative?
- 3 Photonics Companies Making Quantum Tech Possible
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
